LY 326391
Latest Information Update: 28 Nov 2000
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Endometriosis; Postmenopausal osteoporosis
Most Recent Events
- 28 Nov 2000 No-Development-Reported for Breast cancer in USA (Unknown route)
- 28 Nov 2000 No-Development-Reported for Endometriosis in USA (Unknown route)
- 28 Nov 2000 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)